Kilitch Drugs opened lower at ₹237.10, compared with its previous close of ₹239.14. During today's session, the stock has traded between ₹223.20 and ₹243.89, with an average traded price of ₹230.96. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Kilitch Drugs is now worth
₹ 13,813.00
giving a profit of
₹ 3,813.00 (38.13%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-3.88 (-1.62%)
Day High
₹243.89
Day Low
₹223.20
Day Open
₹237.10
Prev Close
₹239.14
Volume
86,071
Value Traded
₹1.99 Cr
1W Return
0.65%
1M Return
26.50%
3M Return
28.49%
6M Return
83.71%
1Y Return
-34.88%
Market Cap (₹ Cr.)
823
PE Ratio
28.60
PB Ratio
2.98
Dividend Yield
-
ROE
10.66%
ROCE
13.15%
Book Value (₹)
79.99
Face Value (₹)
10.00
EPS (TTM)
0.83
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
0.65%
6 Week
-
1 Month
26.50%
3 Month
28.49%
9 Month
-31.73%
Kilitch Drugs AGM passes all resolutions with 95% shareholder support
All four resolutions passed with 95% shareholder support at Kilitch Drugs' 34th AGM. Promoters voted 100% in favor across all agenda items. Public non-institutions split votes nearly evenly at 52.48% for and 47.52% against. Mukund Mehta re-appointed as director retiring by rotation. Performance-linked incentives for executive directors approved as special resolution.
1mo agoKilitch Drugs Q1 Results: Revenue rises 4%, EBITDA margin dips
Kilitch Drugs posted Q1 revenue of ₹449 million, up 4% YoY, but saw EBITDA fall to ₹29 million from ₹33 million. Margins contracted to 6.53% from 7.56%, while net profit dipped slightly to ₹29 million. The results highlight a divergence between top-line growth and operating profitability.
2mo agoKilitch Drugs schedules 34th AGM for Aug 27 via VC/OAVM
Kilitch Drugs (India) Limited holds its 34th AGM on August 27, 2026, using VC/OAVM technology. Remote e-voting is available from August 24 to 26, 2026. The register of members closes from August 20 to 27, 2026, to establish the record date for voting rights.
2mo agoKilitch Drugs posts 4% PAT rise in FY26, seeks ₹2 cr exec pay
Kilitch Drugs posted a 4% rise in consolidated PAT to ₹32.39.96 lakh in FY26, supported by increased export revenue. The firm is convening its AGM to approve ₹2 crore in executive incentives and ratify cost auditor fees.
2mo agoKilitch Drugs commences nutraceutical production at Raigad facility
Kilitch Drugs has started nutraceutical manufacturing at its new plant in Village Maldev, Raigad, Maharashtra, effective June 17, 2026, to strengthen its market presence.
3mo agoKilitch Drugs confirms no share encumbrance in FY26
Kilitch Drugs (India) Limited confirmed no encumbrance over shares held by promoters during FY26. The disclosure was made under SEBI regulations on April 4, 2026.
4mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 5 years ago in Kilitch Drugs is now worth
₹ 13,813.00
giving a profit of
₹ 3,813.00 (38.13%)
Note: Past profits do not guarantee future returns.
